|
Terumo Corporation is a medical technology company organized into four business segments: Cardiovascular, Medical Care Solutions, Blood & Cell Technologies, and Organ Technologies. The group develops and manufactures medical devices and solutions for cardiovascular care, blood management, and organ support. In October 2025, the company acquired all shares of Organox, Ltd., making it a wholly-owned subsidiary and establishing the Organ Technologies segment. The corporate group consists of the parent company, 101 consolidated subsidiaries, and four equity-method affiliates. Summarised from the annual report, fiscal year ended Mar 2026 |
Industry Medical Devices | Homepage terumo.com |
| Sector Healthcare | IR page — | |
|
Tags
cardiovascular devices, blood management, cell technologies, organ support, medical care solutions, Organox Ltd.
|
Press page — |
Metrics
| Valuation | |
|---|---|
| Market cap | ¥ 3.372T |
| Market cap (USD) | $ 21.128B |
| P/E | 29.57 |
| PEG | 1.97 |
| P/BV | 2.11 |
| P/S | 2.76 |
| P/OCF | 12.11 |
| P/FCF | 18.90 |
| Dividend yield | 1.3% |
| Turnover / mcap | — |
| Returns | |
|---|---|
| ROE | 9.2% |
| ROI | 6.9% |
| ROIC | 6.8% |
| Profit margin | 12.0% |
| Growth | |
|---|---|
| Revenue growing | Yes |
| Profits growing | Yes |
| Revenue up 3y | Yes |
| Revenue up 5y | Yes |
| Earnings growth 3y (net profit CAGR) | 15.0% |
| Quality | |
|---|---|
| Profitable | Yes |
| Margin expanding | Yes |
| Buying back stock | No |
| Diluting (TTM) | No |
| Debt/Equity | — |
| Podcast bulls (TTM) | Sign up |
| Podcast bears (TTM) | Sign up |
| Podcast sentiment (TTM) | Sign up |
| Podcast sentiment % (TTM) | Sign up |
| News sentiment (TTM) | 0 |
| Quality score | 31.6% |
| Insiders | |
|---|---|
| Buys, 1w | Sign up |
| Buys, 1m | Sign up |
| Buys, 1y | Sign up |
| Sells, 1w | Sign up |
| Sells, 1m | Sign up |
| Sells, 1y | Sign up |
Sign up to see this company's insider trades
| Figure | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 | FY 2014 | FY 2013 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 1.132T | 1.036T | 921.863B | 820.209B | 703.303B | 613.842B | 628.897B | 599.481B | 587.775B | 514.164B | 525.026B | 489.506B | 467.359B | 402.294B |
| Net profit | 135.914B | 116.978B | 106.374B | 89.325B | 88.813B | 77.268B | 85.211B | 79.47B | 75.59B | 54.225B | 50.676B | 38.47B | 34.096B | 47.014B |
| Free cash flow | 128.889B | 128.437B | 67.556B | 45.363B | 87.952B | 38.361B | 55.163B | 54.245B | — | 44.344B | 47.391B | — | — | — |
| Figure | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 | FY 2014 | FY 2013 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Share price | 2.108K | 2.797K | 2.729K | 3.574K | 3.724K | 3.999K | 3.72K | 3.38K | 5.589K | 3.865K | 4.035K | 3.17K | 2.253K | 2.025K |
| Price performance 12m | -0.25 | 0.02 | -0.24 | -0.04 | -0.07 | 0.08 | 0.1 | -0.4 | 0.45 | -0.04 | 0.27 | 0.41 | 0.11 | — |
Filed figures
Lines the statements and their notes report beside the headline figures, read from the filings' XBRL as filed (no restatement applied), with figures computed from one filing's own lines. Cash-flow lines carry their cash direction: an outflow is negative. Each period links to its filing; a figure's period, report date and tag are in its tooltip.
| Figure | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Balance sheet detail | ||||||||||
| Trade receivables (JPY) | 110B | 121B | 128B | 132B | 129B | 136B | 151B | 179B | 177B | 215B |
| ↳ YoY growth | +4.9% | +5.8% | +2.5% | -2.2% | +5.6% | +10.8% | +18.6% | -1.0% | +21.5% | |
| ↳ 5y CAGR | +4.4% | +6.8% | +6.1% | +10.8% | ||||||
| Borrowings, current (JPY) | 128B | 47.4B | — | 50.3B | 42.1B | 1.12B | 11.2B | 157B | 15B | 280B |
| Borrowings, non-current (JPY) | 211B | 289B | 225B | 196B | 218B | 225B | 221B | 75B | 160B | 99.9B |
| Bonds payable (JPY) | 130B | — | — | — | — | — | — | — | — | — |
| Lease liabilities (JPY) | 461M | — | — | — | — | — | — | — | — | — |
| Cash and deposits (JPY) | 105B | 168B | 123B | 167B | 201B | 205B | 187B | 205B | 222B | 280B |
| Intangible assets (JPY) | 455B | — | — | — | — | — | — | — | — | — |
| Net debt (borrowings + leases - cash) (JPY) | 234B | 168B | 102B | 79.3B | 59.8B | 20.7B | 44.6B | 27B | -47B | 99.3B |
| Cash flow detail | ||||||||||
| Operating cash flow (JPY) | 80.9B | 112B | 93.6B | 117B | 121B | 141B | 118B | 146B | 211B | 231B |
| Purchases of property, plant and equipment (JPY) | -29.8B | -31.9B | -39.3B | -62.3B | -62.3B | -53.5B | -52.7B | -60.7B | -68.6B | -85.2B |
| Purchases of intangible assets (JPY) | -6.68B | -9.46B | -15B | -21.2B | -20.8B | -20.6B | -19.5B | -18B | -13.7B | -16.8B |
| Change in receivables (cash effect) (JPY) | -4.78B | -9.26B | -5.94B | -7.32B | 6.42B | -895M | -8.48B | -16.4B | -4.61B | -23.4B |
| Change in inventories (cash effect) (JPY) | -3.92B | -7.54B | -20.1B | -17.3B | -22B | -8.17B | -39.3B | -9.21B | -11.6B | -7.02B |
| Change in payables (cash effect) (JPY) | 886M | 3.99B | 6.68B | 3.44B | -814M | 55M | 10.5B | -5B | 1.84B | -6.74B |
| Dividends paid (cash effect) (JPY) | -14.5B | -15.8B | -19.6B | -20.5B | -21.2B | -23.5B | -27.9B | -32B | -35.6B | -41.3B |
| Share buybacks (cash effect) (JPY) | -44.2B | -6M | -9M | -3M | -3M | -3M | -50.1B | -11.1B | -30.1B | -1M |
| Interest paid (cash effect) (JPY) | -1.19B | -1.13B | -1.12B | -956M | -1.06B | -1.31B | -1.37B | -1.3B | -1.71B | -2.76B |
| Income taxes paid (cash effect) (JPY) | -24.8B | — | — | — | — | — | — | — | — | — |
| Operating cash flow before change in receivables (JPY) | 85.6B | 124B | 99.5B | 125B | 115B | 142B | 126B | 163B | 215B | 254B |
| Free cash flow (OCF - PPE - intangibles) (JPY) | 44.3B | 73.2B | 39.2B | 34B | 38.4B | 67.4B | 45.4B | 67.6B | 128B | 129B |
| Income detail | ||||||||||
| Research and development expense (JPY) | 33.7B | 41.3B | 47.7B | 50.6B | 49.1B | 51.8B | 61.6B | 69.1B | 74.2B | 76.9B |
| ↳ 5y CAGR | +8.3% | +7.7% | +8.0% | +9.4% | ||||||
| Total comprehensive income (JPY) | 36.5B | 55.1B | 98.9B | 59.2B | 116B | 178B | 176B | 259B | 107B | 257B |
| Comprehensive income to owners (JPY) | 49.7B | 67.7B | 99.1B | 59.4B | 116B | 178B | 176B | 259B | 107B | 257B |
| Segments | ||||||||||
| Blood And Cell Technologies Company · Segment revenue (JPY) | — | — | 105B | 107B | 109B | 121B | 148B | 168B | 200B | 231B |
| ↳ YoY growth | +2.1% | +2.2% | +10.1% | +22.4% | +14.0% | +19.0% | +15.4% | |||
| Blood And Cell Technologies Company · Segment operating income (JPY) | — | — | 15.7B | 15.1B | 19.1B | 20.8B | 11.2B | 16.4B | 26.5B | 33.6B |
| Blood Management Company · Segment revenue (JPY) | — | 105B | 105B | — | — | — | — | — | — | — |
| ↳ YoY growth | +0.3% | |||||||||
| Blood Management Company · Segment operating income (JPY) | — | 15.1B | 15.7B | — | — | — | — | — | — | — |
| Cardiac And Vascular Company · Segment revenue (JPY) | — | 324B | 329B | 351B | 329B | 397B | 481B | 556B | 624B | 676B |
| ↳ YoY growth | +1.4% | +6.7% | -6.3% | +20.9% | +21.0% | +15.6% | +12.4% | +8.3% | ||
| Cardiac And Vascular Company · Segment operating income (JPY) | — | 83.6B | 80.9B | 86.9B | 74.4B | 93.2B | 112B | 124B | 155B | 164B |
| General Hospital Company · Segment revenue (JPY) | — | 159B | 166B | 171B | 176B | — | — | — | — | — |
| ↳ YoY growth | +4.4% | +3.1% | +2.7% | |||||||
| General Hospital Company · Segment operating income (JPY) | — | 26.8B | 26.8B | 25.2B | 25.7B | — | — | — | — | — |
| Medical Care Solutions Company · Segment revenue (JPY) | — | — | — | — | 176B | 185B | 192B | 198B | 211B | 216B |
| ↳ YoY growth | +5.6% | +3.5% | +3.0% | +6.9% | +2.3% | |||||
| Medical Care Solutions Company · Segment operating income (JPY) | — | — | — | — | 25.7B | 23.6B | 14.8B | 19.8B | 23B | 21.6B |
| Terumo Organ Technologies · Segment revenue (JPY) | — | — | — | — | — | — | — | — | — | 7.99B |
| Terumo Organ Technologies · Segment operating income (JPY) | — | — | — | — | — | — | — | — | — | 1.67B |
| Reported | Jun 25, 2018 | Jun 24, 2019 | Jun 26, 2020 | Jun 26, 2020 | Jun 23, 2022 | Jun 23, 2022 | Jun 28, 2023 | Jun 27, 2024 | Jun 23, 2025 | Jun 23, 2026 |
Sign up to see institutional holdings
Sign UpPodcast Mentions
Sign up to see podcast mentions and sentiment
Sign UpTimely disclosures published on TDnet, newest first, titles as filed in Japanese. The link opens the disclosure on TDnet. Filings with EDINET (periodic reports, extraordinary reports, offerings, holding and buy-back reports), newest first, titles as filed in Japanese. The link opens the filing on EDINET. Press releases from the company's own website, newest first.
Prompts
Click prompts to add them under the company line, click again to take one out, then copy the result into your AI chat. Shared by Asian Century Stocks and Uncovered Thai Stocks. Thank you.
ETFs Holding Terumo Corporation
Exchange-traded funds whose newest published daily portfolio holds one of the company's listings, largest weight first.
| ETF | Weight in ETF | Shares | Market value | As of |
|---|---|---|---|---|
| AIVI | 0.23% | 9,700 | $ 133.332K | Jun 30, 2026 |
| UMMA | 0.22% | 40,676 | $ 640.852K | Aug 31, 2026 |
| NTSI | 0.11% | 38,700 | $ 531.954K | Jun 30, 2026 |
| DFAI | 0.09% | 1,024,400 | $ 16.388M | Nov 12, 2026 |
| DFIC | 0.07% | 715,000 | $ 11.438M | Nov 12, 2026 |
| DXIV | 0.05% | 8,000 | $ 127.98K | Nov 12, 2026 |
| DFSI | 0.05% | 35,900 | $ 574.31K | Nov 12, 2026 |
| AVDE | 0.04% | 493,900 | $ 7.545M | Nov 16, 2026 |
| DFAX | 0.02% | 182,600 | $ 2.921M | Nov 12, 2026 |
| AVSD | 0.00% | 1,000 | $ 15.276K | Nov 16, 2026 |
Top


